International Journal of Clinical Practice · 2003 · 21 citations · 19 references
MedicineClinical SciencesPharmacotherapyClinical PharmacologyPharmaceutical CareRheumatologyAutoimmune Rheumatic DiseasesClinical TrialsInflammatory ArthritisRheumatoid ArthritisComparative Clinical TrialsRheumatoid Arthritis PharmacotherapyRheumatoid Arthritis Therapy
SUMMARY Leflunomide (Arava) was approved for the treatment of rheumatoid arthritis by the regulatory authorities in the US and Europe in 1998. This approval was based on three pivotal randomised clinical trials conducted in the US and Europe. This report will focus on the use of leflunomide in rheumatoid arthritis based on the data from these trials as well information on the efficacy and safety learned from post release clinical experience.
19